TD Private Client Wealth’s GSK GSK Stock Holding History

TD Private Client Wealth’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$701K	Sell	12,710 -58,077	-82%	-$3.15M	0.01%	423
2025 Q4	$3.47M	Sell	70,787 -16,404	-19%	-$765K	0.07%	174
2025 Q3	$3.76M	Buy	87,191 +9,172	+12%	+$358K	0.08%	162
2025 Q2	$3M	Buy	78,019 +70,910	+997%	+$2.71M	0.07%	191
2025 Q1	$275K	Buy	7,109 +4,383	+161%	+$160K	0.01%	543
2024 Q4	$92.2K	Sell	2,726 -9,696	-78%	-$349K	﹤0.01%	727
2024 Q3	$508K	Buy	12,422 +3,346	+37%	+$137K	0.01%	455
2024 Q2	$349K	Buy	9,076 +26	+0.3%	+$1.09K	0.01%	489
2024 Q1	$388K	Buy	9,050 +1,768	+24%	+$72.9K	0.01%	481
2023 Q4	$270K	Sell	7,282 -159	-2%	-$5.71K	0.01%	512
2023 Q3	$270K	Sell	7,441 -5,735	-44%	-$204K	0.01%	497
2023 Q2	$470K	Buy	13,176 +4,071	+45%	+$146K	0.02%	448
2023 Q1	$324K	Buy	9,105 +6,796	+294%	+$238K	0.01%	481
2022 Q4	$81.1K	Sell	2,309 -14,111	-86%	-$470K	﹤0.01%	656
2022 Q3	$483K	Buy	16,420 +1,151	+8%	+$43.6K	0.02%	408
2022 Q2	$831K	Buy	15,269 +1,043	+7%	+$57.6K	0.04%	344
2022 Q1	$775K	Buy	14,226 +4,889	+52%	+$266K	0.03%	368
2021 Q4	$515K	Buy	9,337 +3,511	+60%	+$183K	0.02%	415
2021 Q3	$278K	Sell	5,826 -1,496	-20%	-$75.1K	0.01%	483
2021 Q2	$364K	Sell	7,322 -1,464	-17%	-$70.3K	0.02%	445
2021 Q1	$392K	Sell	8,786 -12,827	-59%	-$582K	0.02%	426
2020 Q4	$994K	Sell	21,613 -63,107	-74%	-$2.9M	0.05%	302
2020 Q3	$3.99M	Sell	84,720 -10,487	-11%	-$525K	0.22%	100
2020 Q2	$4.85M	Sell	95,207 -18,722	-16%	-$961K	0.28%	73
2020 Q1	$5.4M	Buy	+113,929	New	+$6.08M	0.39%	57

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TD Private Client Wealth's GSK Position: Q1 2026 in Review

TD Private Client Wealth reduced its GSK (GSK) stake by 82% in Q1 2026, selling an estimated $3.15M and leaving 12,710 shares worth $701K. The position accounts for 0.01% of the portfolio, ranked #423.

TD Private Client Wealth first reported a position in GSK in Q1 2020 and has held it in 25 quarters since. The position peaked at $5.4M in Q1 2020. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

TD Private Client Wealth held 12,710 shares of GSK worth $701K as of Q1 2026.
TD Private Client Wealth sold 58,077 GSK shares in Q1 2026, an estimated $3.15M.
GSK made up 0.01% of TD Private Client Wealth's portfolio in Q1 2026, its #423 holding.
TD Private Client Wealth first reported a position in GSK in Q1 2020 and has held it in 25 quarters since.
TD Private Client Wealth's GSK position peaked at $5.4M in Q1 2020.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.